Granules India Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Granules India Ltd is ₹ 693.2 as of 04 May 09:18 . The P/E Ratio of Granules India Ltd changed from 18.4 on March 2022 to 13.7 on March 2021 . This represents a CAGR of -5.73% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Granules India Ltd changed from ₹ 7596 crore on March 2022 to ₹ 7511 crore on March 2021 . This represents a CAGR of -0.22% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Granules India Ltd for the Mar '26 is ₹ 1495 crore as compare to the Dec '25 revenue of ₹ 1384 crore. This represent the growth of 8.02% The revenue of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 120.64 crore. This represent the decline of -100% The ebitda of Granules India Ltd for the Mar '26 is ₹ 376.79 crore as compare to the Dec '25 ebitda of ₹ 304.46 crore. This represent the growth of 23.76% The ebitda of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 26.71 crore. This represent the decline of -100% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 201.57 crore over 8 quarters. This represents a CAGR of 22.35% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Granules India Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Granules India Ltd or Syncom Formulations (India) Ltd?

Market cap of Granules India Ltd is 17,327 Cr while Market cap of Syncom Formulations (India) Ltd is 1,290 Cr

What are the key factors driving the stock performance of Granules India Ltd and Syncom Formulations (India) Ltd?

The stock performance of Granules India Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Granules India Ltd and Syncom Formulations (India) Ltd?

As of May 4, 2026, the Granules India Ltd stock price is INR ₹699.25. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹13.73.

How do dividend payouts of Granules India Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Granules India Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.